Novel and engineered anti-B-cell monoclonal antibodies for non-Hodgkin's lymphoma

Peter Martin; Richard R Furman; Jia Ruan; Rebecca Elstrom; Jacqueline Barrientos; Ruben Niesvizky; Morton Coleman; John P Leonard

doi:10.1053/j.seminhematol.2008.02.007

Novel and engineered anti-B-cell monoclonal antibodies for non-Hodgkin's lymphoma

Semin Hematol. 2008 Apr;45(2):126-32. doi: 10.1053/j.seminhematol.2008.02.007.

Authors

Peter Martin¹, Richard R Furman, Jia Ruan, Rebecca Elstrom, Jacqueline Barrientos, Ruben Niesvizky, Morton Coleman, John P Leonard

Affiliation

¹ Center for Lymphoma and Myeloma, Division of Hematology-Oncology, Department of Medicine, Weill Cornell Medical College and New York Presbyterian Hospital, New York, NY 10021, USA.

PMID: 18381108
DOI: 10.1053/j.seminhematol.2008.02.007

Abstract

Over the past decade, the safety and efficacy of the anti-CD20 antibody rituximab has resulted in its use in virtually all patients with B-cell non-Hodgkin's lymphoma (NHL). Unfortunately, many patients who initially benefit from rituximab develop resistance while others may never respond. Both the successes and limitations of rituximab have heralded an explosion in research and development of novel monoclonal antibodies. Strategies employed to improve upon rituximab have included developing antibodies to target new epitopes of CD20 and new antigens, humanizing or creating fully human antibodies, and engineering antibodies with a potentially greater capacity for interaction with the host immune system. Each of these strategies has shown varying degrees of preclinical and clinical success. In this review we discuss the rationale for various strategies and report results from clinical trials employing these agents.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Antibodies, Monoclonal / immunology
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Murine-Derived
Antibodies, Neoplasm / immunology
Antibodies, Neoplasm / therapeutic use*
Antibody-Dependent Cell Cytotoxicity
Antigens, CD20 / immunology
Antigens, Differentiation, B-Lymphocyte / immunology
Antigens, Neoplasm / immunology
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
B-Lymphocytes / immunology*
B7-1 Antigen / immunology
CD40 Antigens / immunology
Clinical Trials as Topic
Drugs, Investigational / therapeutic use
Humans
Lymphoma, Non-Hodgkin / drug therapy*
Lymphoma, Non-Hodgkin / immunology
Mice
Rituximab
Sialic Acid Binding Ig-like Lectin 2 / immunology

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Murine-Derived
Antibodies, Neoplasm
Antigens, CD20
Antigens, Differentiation, B-Lymphocyte
Antigens, Neoplasm
B7-1 Antigen
CD40 Antigens
Drugs, Investigational
Sialic Acid Binding Ig-like Lectin 2
Rituximab